CNC — Centene Corp.

The market has re-rated CNC hard off the 2025 trough: the stock is up 92.8% over six months (52-week range $31.63-$69.36) after the July 28, 2026 Q2 print beat and management raised FY26 adjusted EPS guidance from a >$3.40 floor to >$4.80, with consolidated HBR improving to 89.6% from 93.0% a year earlier and commercial HBR at 79.2%. Sell-side positioning is constructive (FMP shows 27 Buy / 16 Hold / 1 Sell; the research brief cites ~9 Buy / 11 Hold / 1 Sell among active covering analysts) with consensus targets clustered at $68.29-$74.64, i.e. roughly 3-12% above the 2026-09-13 price. Two things temper it: price has gone nowhere for a month (-0.97% 1-mo, -0.92% 1-wk), and late-August open-market sales by executives (including General Counsel Christopher Koster) plus the announced retirement of CFO Drew Asher at end-2026 give bulls a reason to pause rather than chase.

The trend is an inflection off a trough, not a structural decline - but it is a violent, lumpy one. Revenue went from $163.1B in FY2024 to $194.8B in FY2025 (+19.4%, driven by Medicaid/ACA rate and membership), and has now stalled: H1 2026 revenue of $94.3B is down 1.1% YoY versus H1 2025's $95.4B, consistent with FY26 guidance of $193.5-197.5B (roughly -0.7% to +1.4%) as redeterminations shrink membership 8-9%. (Note a data conflict: the FMP income statement shows Q2 2026 revenue of $44.4B, down 9% YoY, while the research brief cites $53.58B - the guidance math is more consistent with the FMP series.) Margins tell the real story: quarterly operating margin ran 2.7%/3.1% in Q1/Q2 2024 and 3.3% in Q1 2025, then collapsed to -0.94% (Q2 2025, ACA risk-adjustment true-up) and -14.0% (Q3 2025, a ~$6.95B operating loss / impairment) and -3.50% (Q4 2025), before snapping back to 3.73% in Q1 2026 and 3.10% in Q2 2026. Diluted EPS followed the same path: 2.16, 2.16, 1.36, 0.56 through 2024; -0.51, -13.50, -2.24 through mid-2025; then +3.11 and +2.19 in Q1/Q2 2026. Two cautions: Q1+Q2 2026 GAAP EPS of $5.30 already exceeds the full-year adjusted guidance floor of $4.80, implying management expects a weak or loss-making H2 (Centene has a genuine H2 seasonality problem - H2 2025 was deeply negative), and the balance sheet lost roughly $4.8B of book equity in twelve months ($27.4B at 2025-06-30 to $22.6B at 2026-06-30). Free cash flow is the standout: $4.20B in Q2 2026 and ~$9.0B TTM, versus negative FCF quarters as recently as Q3/Q4 2024.

Cheap versus its own history, roughly fair-to-modestly-cheap on forward earnings. The headline numbers are useless: P/E TTM is -6.4x and EPS TTM is -$10.33 because of the 2025 impairments, and PEG of 0.018 is an artifact of that negative base. What matters as of 2026-09-13: the stock's $66.40 price is ~13.8x the guided FY26 adjusted EPS floor of $4.80 and ~13.8x FMP's next-FY consensus estimate of $4.802 - undemanding for a business guiding to >$4.80 from a prior >$3.40 floor. P/S of 0.169 is a ~32% discount to the 5-year average of 0.25 (the 5-year average P/E of 24.85x is not comparable given the current negative trailing base, hence the 'Cheap vs. its own history' 95.2 valuation-context score). P/B of 1.45x on $45.67/share of book is in line with where MCOs trade, and TTM free cash flow of ~$9.0B is an eye-catching 27% of market cap, though that figure is inflated by working-capital/claims-float timing and should be normalized closer to $5-6B (still a 15-18% FCF yield). Net of $24.2B cash against $16.0B long-term debt, enterprise value is ~$24.7B - but much of that cash is regulated-subsidiary float, so don't over-read it. Bottom line: you are paying a normal multiple for a normalized recovery, not a distressed multiple.

The stock has already been paid for the first leg of the recovery - it doubled in six months while trailing EPS was still negative, so the market is pricing forward, not trailing. At ~13.8x FY26 guidance, the multiple is not demanding, but there is now very little cushion for a miss: if H1 2026 GAAP EPS of $5.30 is real, then FY26 guidance of >$4.80 requires a roughly break-even-to-negative H2, and any Q3 HBR re-deterioration or new ACA risk-adjustment accrual would make that 89.6% consolidated HBR look like a peak rather than a run-rate. The upside case requires FY2027 EPS to move toward $5.50-$6.00 (my estimate), which at a 13-14x multiple is a $72-$84 stock; the downside case is a return toward 10-11x on a $4.50 earnings base ($45-$50) if Medicaid rate pressure or ACA subsidy expiry bites. Net: the easy re-rating is done, and the next move depends on whether Q3/Q4 confirm the margin recovery or expose it as a one-off.

As of 2026-09-13, the trend is up but the momentum has clearly stalled. RSI(14) was 53.49 - dead neutral, well off any oversold reading and no longer overbought, consistent with a market that has digested a big move. Price at $66.40 was 1.44% above the 20-day SMA (~$65.46) and 1.43% above the 50-day SMA (~$65.46), which have converged and flattened - a textbook consolidation. The 200-day SMA sat near $50.90, putting price 30.45% above it, an extended reading that leaves the stock vulnerable to mean-reversion if the sector wobbles. Returns: +92.8% over six months, but only +1.89% over three months, -0.97% over one month and -0.92% over one week. Entry-timing implication: this is a 'buy weakness, don't chase strength' setup - accumulation into the $63-$65.50 zone (SMA20/50 support) offers a defined risk point, whereas buying above $69-$70 with the stock already up 93% and no fresh catalyst until October is poor risk/reward.

• Medicaid redeterminations/eligibility unwinding: membership is expected to contract ~8-9% through 2026, which caps revenue (FY26 guidance of $193.5-197.5B is roughly flat vs. FY25's $194.8B) and puts all the earnings burden on margin rather than volume.
• ACA Marketplace policy risk: the enhanced premium tax credits and 2027 rate filings are unresolved; Centene's commercial HBR of 79.2% in Q2 2026 is excellent, but Q2 2025's -$0.51 EPS showed how fast risk-adjustment dynamics can flip marketplace economics.
• Medicare Advantage regulation: CMS Stars ratings and rate notices drive bonus revenue and Part D margin; the October 2026 release of 2027 cutpoints is the swing factor, with recent street analysis suggesting the cutpoints are more manageable than feared (a mild tailwind).
• Sector-wide medical cost trend: elevated outpatient/procedural utilization has kept managed-care margins under scrutiny across the industry; Centene's pricing discipline has mitigated it so far but this is the single biggest swing factor in the HBR.
• Rates and capital structure: $16.0B of long-term debt against $22.6B of equity (0.71 debt/equity) means refinancing costs matter, while the $24.2B cash/investment balance earns float income that is sensitive to short rates.
• Policy headline risk: any federal action on Medicaid funding formulas or eligibility rules is an existential-scale variable for a company whose revenue is overwhelmingly government-paid.

• Q3 2026 earnings (late October/early November 2026): the first real test of whether the 89.6% consolidated HBR is a run-rate and whether the >$4.80 FY26 guidance survives a seasonally weak H2.
• CMS 2027 Medicare Advantage Star Ratings release (early October 2026): determines bonus-payment visibility for Centene's Medicare book and is a sector-wide swing event.
• Resolution or extension of ACA enhanced premium subsidies and 2027 marketplace rate approvals - determines marketplace margin durability into FY2027.
• CFO succession: Drew Asher retires at end-2026; the identity/quality of the successor is a governance and forecasting-credibility signal.
• Capital deployment: with ~$9.0B TTM free cash flow and a 1.45x P/B, buybacks or debt reduction at current prices would be accretive and would signal management's own view of intrinsic value.
• Continued Medicaid margin recovery if redetermination-driven disenrollment proves more favorable to acuity mix than the 8-9% membership decline implies.

• H2 2026 guidance arithmetic: H1 2026 GAAP diluted EPS of $5.30 already exceeds the full-year adjusted guidance floor of >$4.80, implying management expects a weak or money-losing H2 - if that expectation is wrong in the other direction (a bigger-than-expected loss), the recovery narrative breaks.
• ACA marketplace and risk-adjustment volatility: the Q2 2025 loss (-$0.51 EPS) and the 2025 impairment cycle show this book can swing violently; unresolved subsidy policy makes FY2027 marketplace margins unknowable today.
• Medicaid rate pressure: state budgets are squeezed, and a roughly flat revenue base means any failure to hold the improved HBR flows straight to the bottom line.
• Balance-sheet erosion: stockholders' equity fell from $27.4B (2025-06-30) to $22.6B (2026-06-30), and TTM net margin is -2.6% with ROE of -33.4% - the book value supporting the 1.45x P/B is lower-quality than a year ago.
• Extended technicals and insider selling: price is 30.45% above its 200-day SMA as of 2026-09-13 and late-August open-market sales by executives (e.g. General Counsel Christopher Koster) plus the CFO retirement announcement are the kind of signals that tend to appear after a 93% run, not before it.
• Sector-wide utilization shock: an acceleration in medical cost trend would hit an insurer with a 16.1% gross margin and ~3% operating margin far harder than a diversified healthcare name.

Centene is a genuinely improving business trading at a reasonable price - not a bargain and not a trap. The evidence for improvement is concrete: HBR down to 89.6% from 93.0%, Q2 2026 operating margin of 3.10% after two consecutive loss quarters, FY26 EPS guidance raised from >$3.40 to >$4.80 on July 28, 2026, and ~$9.0B of TTM free cash flow. But the stock has already banked that: up 92.8% in six months, it now trades at ~13.8x forward earnings with roughly 8% upside to my $72 fair value, revenue is flat-to-down as Medicaid membership shrinks 8-9%, book equity has fallen $4.8B in a year, and the guidance itself implies a loss-making H2. That is a 'own it on weakness, don't chase it at $66' setup rather than a fresh buy, which is why the balanced/directional lean here is Neutral and not bullish - the recovery is real, but it is now consensus, and the next 20% depends on Q3/Q4 execution and the October Stars decision.

Forward P/E applied to FY2027E EPS, because the trailing P/E of -6.4x is meaningless after the 2025 impairments. Inputs: FY2026E adjusted EPS of $4.80 (company guidance floor, matching FMP's next-FY consensus of $4.802); FY2027E EPS of $5.55, a ~16% step-up from continued HBR normalization (89.6% consolidated, 79.2% commercial) on roughly flat revenue, partly offset by Medicaid membership contraction and unresolved ACA subsidy policy; and a justified multiple of 13.0x - well below the 5-year average trailing P/E of 24.85x (not comparable post-impairment) but at the upper half of the ~10-14x forward range for Medicaid-heavy managed care, supported by a 0.169x P/S versus a 0.25x five-year average. 13.0 x $5.55 = $72.15, rounded to $72.00.